| Item |
Information |
|
Drug Groups
|
approved |
|
Description
|
A competitive histamine H2-receptor antagonist. Its main pharmacodynamic effect is the inhibition of gastric secretion. [PubChem] |
| Indication |
For the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). |
| Pharmacology |
Famotidine, a competitive histamine H2-receptor antagonist, is used to treat gastrointestinal disorders such as gastric or duodenal ulcer, gastroesophageal reflux disease, and pathological hypersecretory conditions. Famotidine inhibits many of the isoenzymes of the hepatic CYP450 enzyme system. Other actions of Famotidine include an increase in gastric bacterial flora such as nitrate-reducing organisms. |
| Toxicity |
Intravenous, mouse: LD50 = 244.4mg/kg; Oral, mouse: LD50 = 4686 mg/kg. Symptoms of overdose include emesis, restlessness, pallor of mucous membranes or redness of mouth and ears, hypotension, tachycardia and collapse. |
| Affected Organisms |
| • |
Humans and other mammals |
|
| Biotransformation |
Hepatic. |
| Absorption |
The bioavailability of oral doses is 40-45%. |
| Half Life |
2.5-3.5 hours |
| Protein Binding |
15-20% |
| Elimination |
Renal clearance is 250-450 mL/min, indicating some tubular excretion. |
| Clearance |
* renal cl=250-450 mL/min |
| External Links |
|